PharmAbcine Inc. has entered into a research collaboration with Wuxi Shuangliang Biotechnology (SLBio) to evaluate the combination of each party’s clinical candidate, olinvacimab and C-005, a 3rd generation of EGFR inhibitor with superior brain-blood-barrier permeability, in treating non-small cell lung cancer (NSCLC). NSCLC is the leading cause of cancer-related deaths in the U.S. and China.

PharmAbcine’s Olinvacimab has shown impressive safety profile and efficacy in clinical studies. It is currently in a Phase II trial in Australia and the U.S. in bevacizumab non responding rGBM patients. In addition, two Phase Ib combination trials of olinvacimab and pembrolizumab are ongoing in mTNBC and in rGBM patients. It has been shown in previous rGBM Phase IIa trial that numerous rGBM patients have improved their cerebral edema condition by olinvacimab treatment.

SLBio’s C-005 is a novel 3rd-generation EGFR inhibitor. Preclinical studies have shown C-005 has strong BBB penetrating properties and best-in-class safety profile. A Phase I trial in China is ongoing in EGFRm+ NSCLC patients. Preliminary Phase I data have demonstrated promising efficacy and safety profiles.